Logo

Junshi Biosciences and Coherus Publishes Results of Toripalimab in P-III (JUPITER-06) Study for Esophageal Squamous Cell Carcinoma in Cancer Cell

Share this
Junshi Biosciences and Coherus Publishes Results of Toripalimab in P-III (JUPITER-06) Study for Esophageal Squamous Cell Carcinoma in Cancer Cell

Junshi Biosciences and Coherus Publishes Results of Toripalimab in P-III (JUPITER-06) Study for Esophageal Squamous Cell Carcinoma in Cancer Cell

Shots:

  • The P-III (JUPITER-06) study evaluates toripalimab + TP vs PBO + TP in a ratio (1:1) in 514 patients with advanced or metastatic ESCC at 72 centers across China
  • The trial met its co-primary EPs i.e., improvement in OS & PFS, m-OS (17mos. vs 11mos.), 1yr. OS rates (66.0% vs 43.7%), m-PFS (5.7mos. vs 5.5mos.), 1yr. PFS rates (27.8% vs 6.1%), PFS & OS benefits were observed across all PD-L1 expression subgroups, including in patients with low PD-L1 expression
  • The incidence of grade >3 TEAEs was similar b/w both arms, 99.2% of patients experienced 1 TEAE with no new safety signals. The company plan to file an additional toripalimab’s BLAs with the US FDA over the next 3yrs. for other cancer

Ref: Globe Newswire | Image: PR Newswire

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions